

# Towards the Modulation of RNA-Binding Proteins: New Compounds Targeting Protein HuR †

Serena Della Volpe <sup>1</sup>, Rita Nasti <sup>1</sup>, Michele Queirolo <sup>1</sup>, Yagiz M. Unver <sup>2,3</sup>, Varsha R. Jumde <sup>2,3</sup>, Alexander Dömling <sup>4</sup>, Francesca Vasile <sup>5,\*</sup>, Donatella Potenza <sup>5</sup>, Francesca Alessandra Ambrosio <sup>6</sup>, Giosué Costa <sup>6</sup>, Stefano Alcaro <sup>6</sup>, Chiara Zucal <sup>7</sup>, Alessandro Provenzani <sup>7</sup>, Marcello Di Giacomo <sup>1</sup>, Daniela Rossi <sup>1</sup>, Anna K. H. Hirsch <sup>2,3,\*</sup> and Simona Collina <sup>1</sup>

<sup>1</sup> Department of Drug Sciences, Medicinal Chemistry and Technology Section, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy; [serena.dellavolpe01@universitadipavia.it](mailto:serena.dellavolpe01@universitadipavia.it) (S.D.V.);

[rita.nasti01@universitadipavia.it](mailto:rita.nasti01@universitadipavia.it) (R.N.); [michele.queirolo@ceradis.com](http://michele.queirolo@ceradis.com) (M.Q.);

[marcello.digiacom@unipv.it](mailto:marcello.digiacom@unipv.it) (M.D.G.); [daniela.rossi@unipv.it](mailto:daniela.rossi@unipv.it) (D.S.); [simona.collina@unipv.it](mailto:simona.collina@unipv.it) (S.C.)

<sup>2</sup> Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, NL-9747 AG, Groningen, The Netherlands; [yagizunver@gmail.com](mailto:yagizunver@gmail.com) (Y.M.U.); Varsha.Jumde@helmholtz-hips.de (V.K.J.)

<sup>3</sup> Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)—Helmholtz Centre for Infection Research (HZI), Department of Drug Design and Optimization and Department of Pharmacy, Saarland University, Campus Building E8.1, 66123 Saarbrücken, Germany

<sup>4</sup> Department of Drug Design, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands; [a.s.s.domling@rug.nl](mailto:a.s.s.domling@rug.nl)

<sup>5</sup> Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy; [donatella.potenza@unimi.it](mailto:donatella.potenza@unimi.it)

<sup>6</sup> Department of Health Sciences, University “Magna Græcia” of Catanzaro, Viale Europa, 88100 Catanzaro, Italy; [ambrosio@unicz.it](mailto:ambrosio@unicz.it) (F.A.A.); [gcosta@unicz.it](mailto:gcosta@unicz.it) (G.C.); [alcaro@unicz.it](mailto:alcaro@unicz.it) (S.A.)

<sup>7</sup> Department of CIBIO, University of Trento, Via Sommarive 9, 38123 Povo, TN, Italy; [chiara.zucal@unitn.it](mailto:chiara.zucal@unitn.it) (C.Z.); [Alessandro.Provenzani@unitn.it](mailto:Alessandro.Provenzani@unitn.it) (A.P.)

\* Correspondence: [francesca.vasile@unimi.it](mailto:francesca.vasile@unimi.it) (F.V.); Anna.Hirsch@helmholtz-hzi.de (A.K.H.H.)

† Presented at the 2nd Molecules Medicinal Chemistry Symposium (MMCS): Facing Novel Challenges in Drug Discovery, Barcelona, Spain, 15–17 May 2019.

Received: date; Accepted: date; Published: date

**Keywords:** RNA-binding protein; multi-component reactions; STD-NMR.

RNA-binding proteins (RBPs) have been widely recognized for their pivotal role in the regulation of post-transcriptional processes. Particularly, their complexes with RNA are involved in numerous dysfunctions (*i.e.*, cancer, inflammation, and neurodegeneration) and thus pose the interesting question of whether they could be used as therapeutic targets with clinical relevance [1].

The research efforts of our team in this field have been dedicated to the identification of compounds able to modulate protein–RNA interactions, with a special focus on the ELAV (embryonic lethal abnormal vision) protein family [2,3]. Our first medicinal chemistry synthetic campaign exploited a structure-based approach for the design of novel HuR ligands based on different scaffolds. The synthesis of representative compounds of each series was accomplished through multicomponent reactions or equally efficient processes. Afterwards, the structural elucidation of their interaction with HuR was carried out according to an STD (saturation transfer difference)-NMR and *in silico* combined strategy [4].

In this communication, we move a step forward in understanding the structural features essential for the interaction with HuR. The information thus obtained represents the basis to identify compounds able to interfere with HuR–RNA complexes, therefore modulating gene expression.

## References

1. Hentze, M.W.; Castello, A.; Schwarzl, T.; Preiss, T. A brave new world of RNA-binding proteins. *Nat. Rev. Mol. Cell Biol.* **2018**, *19*, 327–341.

2. Nasti, R.; Rossi, D.; Amadio, M.; Pascale, A.; Unver, M.Y.; Hirsch, A.K.H.; Collina, S. Compounds Interfering with Embryonic Lethal Abnormal Vision (ELAV) Protein–RNA Complexes: An Avenue for Discovering New Drugs. *J. Med. Chem.* **2017**, *60*, 8257–8267.
3. Vasile, F.; Della Volpe, S.; Ambrosio, F.A.; Costa, G.; Unver, M.Y.; Zucal, C.; Rossi, D.; Martino, E.; Provenzani, A.; Hirsch, A.K.H.; Alcaro, S.; Potenza, D.; Collina, S. Exploration of ligand binding modes towards the identification of compounds targeting HuR: a combined STD-NMR and Molecular Modelling approach. *Sci. Rep.* **2018**, *8*, 13780.
4. Della Volpe, S.; Nasti, R.; Queirolo, M.; Unver, M.Y.; Jumde, V.R.; Dömling, A.; Vasile, F.; Potenza, D.; Ambrosio, F.A.; Costa G.; Alcaro, S.; Zucal C.; Provenzani, A.; Di Giacomo, M.; Rossi, D.; Hirsch, A.K.H.; Collina, S. Novel Compounds Targeting the RNA-Binding Protein HuR. Structure-Based Design, Synthesis, and Interaction Studies. *ACS Med. Chem. Lett.* **2019**, *104*, 615–620.